abil
veterinarian
obtain
blood
type
potenti
donor
recipi
limit
scarciti
reagent
laboratori
perform
type
anim
blood
time
canin
type
reagent
avaiabl
laboratori
dr
robert
bull
michigan
state
univers
addit
sever
veterinari
school
least
one
commerci
laboratori
stormont
laboratori
vacavil
california
perform
type
canin
blood
use
reagent
case
canin
donor
type
two
allel
locu
antibodi
combin
term
procedur
type
cross
match
see
smith
volum
erythrocyt
dog
react
reagent
commonli
call
posit
red
cell
posit
like
sensit
recipi
lack
antigen
aposit
dog
repres
popul
util
donor
recipi
also
posit
requir
type
avail
recipi
blood
group
dog
may
develop
antibodi
given
ai
red
cell
rare
swisher
young
antibodi
would
detect
major
cross
match
done
subsequ
transfus
although
singl
transfus
aposit
blood
could
given
aneg
dog
never
previous
transfus
antibodi
may
form
increas
risk
reaction
subsequ
transfus
prematur
destruct
transfus
cell
day
first
transfus
neonat
hemolyt
diseas
pup
transfus
bitch
see
paradi
volum
type
immedi
avail
aneg
donor
use
transfus
test
blood
group
antigen
present
dog
routin
done
antigen
may
also
elicit
antibodi
respons
neg
dog
swisher
young
dog
natur
occur
antibodi
although
gener
thought
clinic
signific
r
w
bull
person
commun
observ
shorten
surviv
transfus
cell
dog
remain
antigen
either
weakli
reactiv
els
preval
rare
donor
recipi
like
match
type
done
known
unknown
antigen
dog
receiv
transfus
day
previous
cross
match
major
cross
match
test
donor
red
cell
recipi
plasma
detect
clinic
signific
antibodi
form
previou
transfus
cross
match
prevent
sensit
detect
sensit
alreadi
present
autocontrol
recipi
red
cell
plasma
includ
recipi
immunemedi
hemolysi
autoagglutin
direct
antiglobulin
test
dat
posit
interf
type
cross
match
control
weakli
posit
test
sampl
strong
result
may
valid
equal
conclus
compat
drawn
minor
cross
match
test
donor
plasma
recipi
red
cell
help
dog
felin
type
reagent
readili
avail
although
potenti
incompat
transfus
detect
major
cross
match
frequenc
blood
group
cat
vari
geograph
breed
auer
bell
bird
et
al
giger
giger
greater
cat
unit
state
europ
japan
approxim
australia
blood
group
certain
breed
especi
persian
devon
rex
british
shorthair
himalayan
abyssinian
birman
scottish
fold
somali
high
preval
group
b
breed
giger
orient
breed
siames
burmes
tend
group
felin
transfus
across
blood
group
result
rapid
destruct
transfus
cell
even
recipi
never
previous
transfus
sever
clinic
reaction
seen
group
b
cat
given
group
cell
cat
high
natur
occur
titer
antia
antibodi
less
sever
reaction
seen
group
b
blood
given
group
cat
surviv
transfus
cell
short
practic
approach
felin
transfus
group
donor
avail
type
avail
locat
type
canin
blood
transfus
need
major
cross
match
done
recipi
group
b
cat
strong
agglutin
occur
even
without
use
coomb
reagent
group
b
blood
need
group
b
donor
may
identifi
form
one
highpreval
breed
need
urgent
blood
may
obtain
dr
ur
giger
univers
pennsylvania
hors
compat
test
includ
direct
agglutin
antiglobulin
hemolyt
test
effect
predict
surviv
transfus
fe
label
cell
kallfelz
et
al
despit
lack
evid
incompat
test
transfus
valu
period
day
second
transfus
group
six
hors
result
two
sever
anaphylact
reaction
similar
short
red
cell
surviv
note
label
cross
matchcompat
red
cell
given
normal
cattl
kallfelz
whitlock
day
posttransfus
surviv
fraction
drop
goat
sheep
halflif
transfus
autolog
red
cell
day
gulliani
et
al
gile
et
al
unmatch
homolog
goat
red
cell
transfus
surviv
time
day
cell
remain
circul
seventh
day
like
explan
poor
surviv
transfus
red
cell
hors
rumin
presenc
natur
occur
isoantibodi
numer
blood
group
antigen
transfus
speci
must
given
caution
cross
match
may
predict
incompat
also
surviv
cell
poor
maximum
use
altern
transfus
made
anim
need
transfus
caus
blood
loss
anemia
known
case
anemia
unknown
caus
blood
drawn
test
anticip
transfus
given
test
includ
complet
blood
count
cbc
reticulocyt
count
except
hors
platelet
count
red
cell
indic
morpholog
help
find
caus
dat
run
suspicion
immunemedi
diseas
posit
dat
posttransfus
could
caus
develop
alloantibodi
iron
defici
present
adult
anim
one
search
especi
dilig
bleed
gastrointestin
lesion
ulcer
neoplasia
anemia
nonregen
renal
function
evalu
human
recombin
erythropoietin
shown
effect
treatment
dog
cat
anemia
associ
renal
diseas
cowgil
et
al
examin
marrow
indic
case
nonregen
anemia
unknown
caus
anemia
chronic
diseas
associ
mild
decreas
hematocrit
hct
occur
secondari
mani
chronic
debilit
diseas
hct
drop
addit
problem
must
sought
addit
inform
clinic
workup
anem
patient
provid
elsewher
cotter
red
blood
cell
need
whenev
red
cell
number
becom
deplet
oxygencarri
capac
insuffici
maintain
adequ
perform
definit
adequ
may
vari
exampl
otherwis
healthi
anim
mild
moder
weak
acut
blood
loss
may
allow
recov
spontan
sever
ill
patient
degre
anemia
caus
surgic
blood
loss
may
recov
quickli
fewer
complic
transfus
one
must
avoid
temptat
arbitrari
transfus
given
hct
sever
factor
consid
includ
caus
sever
anemia
expect
blood
loss
altern
treatment
option
time
onset
anemia
typic
anemia
caus
lack
red
cell
product
slow
onset
compensatori
mechan
function
time
anemia
sever
mechan
includ
increas
cardiac
output
pulmonari
ventil
speci
increas
red
cell
thu
oxygen
deliveri
maxim
sedentari
patient
may
show
mild
clinic
sign
despit
hct
less
convers
acut
anem
patient
may
requir
red
cell
support
higher
hct
fact
patient
acut
hemorrhag
may
die
normal
hct
decis
transfus
also
depend
upon
overal
evalu
patient
especi
cardiac
pulmonari
renal
function
avail
altern
treatment
iron
replac
chronic
blood
loss
may
avert
need
blood
ventricular
function
depress
anim
hct
less
howev
oxygen
extract
central
venou
po
remain
normal
hct
reach
messmer
chronic
anem
patient
one
must
consid
benefit
transfus
rais
arteri
oxygen
content
risk
overload
alreadi
hyperkinet
circul
red
cell
may
avail
fresh
store
whole
blood
pack
red
cell
prbc
less
commonli
wash
red
cell
anemia
need
red
cell
prbc
treatment
choic
minim
exposur
donor
histocompat
antigen
citrat
volum
transfus
adjust
individu
patient
need
hct
prbc
approxim
salin
usual
ad
facilit
administr
use
small
volum
congest
heart
diseas
larger
volum
dehydr
hypovolemia
fresh
whole
blood
may
indic
activ
bleed
anem
anim
thrombocytopenia
conveni
fresh
whole
blood
also
use
cat
small
dog
less
kg
ambulatori
larg
anim
practic
blood
may
drawn
one
anim
herd
given
immedi
anoth
although
fresh
whole
blood
may
suppli
platelet
store
whole
blood
contain
viabl
platelet
hour
equip
personnel
avail
make
compon
valu
store
whole
blood
except
would
cat
limit
amount
blood
approxim
ml
drawn
donor
volum
collect
standard
human
blood
bag
citrat
remov
expel
satellit
bag
enough
citrat
left
collect
line
ml
volum
small
plasma
remov
standard
plasma
extractor
present
way
felin
prbc
collect
open
system
occasion
treatment
neonat
hemolyt
diseas
wash
matern
red
cell
may
given
antibodi
remov
plasma
allow
surviv
remain
neonat
red
cell
along
transfus
matern
cell
product
rare
use
anim
use
human
leukocytepoor
red
cell
frozen
red
cell
leukocyt
remov
centrifug
wash
filtrat
techniqu
minim
febril
reaction
may
occur
multipli
transfus
patient
develop
antibodi
histocompat
antigen
donor
white
cell
freez
red
cell
practic
longterm
storag
rare
type
autolog
unit
remov
unwant
histocompat
antigen
process
freez
preserv
dog
red
cell
describ
somewhat
expens
time
consum
practic
routin
veterinari
use
contrera
et
al
addit
dog
red
cell
prone
hemolysi
process
human
cell
freez
red
cell
may
use
longterm
storag
rare
speci
valuabl
anim
donor
may
avail
transfus
need
variou
formula
deriv
estim
hct
increment
expect
recipi
red
cell
transfus
assum
transfus
cell
surviv
normal
recipi
normal
blood
volum
exampl
whole
blood
given
dehydr
anim
period
hct
measur
immedi
afterward
hour
later
one
observ
initi
rise
hct
follow
rise
hour
fluid
shift
vasculatur
interstitium
secondari
drop
hct
might
occur
anim
given
prbc
fluid
drawn
vasculatur
effect
red
cell
simpl
rule
thumb
transfus
mlkg
whole
blood
mlkg
prbc
rais
hct
recipi
point
practic
reason
canin
blood
drawn
human
unit
bag
hold
ml
blood
store
approxim
unit
prbc
unit
plasma
transfus
except
dog
weigh
less
pound
given
unit
volum
hct
rais
clinic
safe
rang
cat
unit
often
defin
ml
maximum
amount
safe
drawn
cat
intraven
rout
use
transfus
except
tini
pup
kitten
true
even
cutdown
requir
access
indwel
cathet
place
vein
transfus
given
slowli
without
need
restrain
recipi
ent
needl
size
least
gaug
even
cat
absorpt
intraperiton
rout
slow
inconsist
wherea
intramedullari
transfus
allow
cell
enter
circul
within
minut
clark
woodley
rate
blood
given
depend
upon
sever
factor
gener
transfus
complet
within
hour
accord
stan
dard
set
american
associ
blood
bank
widmann
prevent
growth
bacteria
event
contamin
case
acut
massiv
hemorrhag
blood
may
pump
within
minut
full
hour
use
case
cardiac
insuffici
either
primari
secondari
chronic
anemia
routin
transfus
treatment
anemia
necessari
warm
blood
take
refriger
unopen
bag
salin
may
store
waterbath
use
dilut
prbc
transfus
need
warm
blood
indic
neona
tal
transfus
administr
hypotherm
patient
hypo
thermia
caus
vasoconstrict
also
interfer
platelet
func
tion
valeri
et
al
warm
done
waterbath
thermostat
standard
blood
warmer
blood
heat
temperatur
greater
hemolysi
occur
blood
administr
set
filter
use
prevent
clot
enter
recipi
microaggreg
filter
indic
routin
transfus
use
massiv
transfus
store
blood
microaggreg
white
cell
platelet
accumul
contribut
pulmonari
insuffici
transfus
compat
cell
store
standard
citrat
anticoagu
lant
normal
surviv
transfus
autolog
homol
ogou
transfus
cell
label
cr
isotop
persist
circul
studi
see
smith
volum
erythrocyt
compat
red
cell
remov
steadili
period
time
normal
red
cell
life
span
speci
transfus
blood
contain
cell
age
transfus
cell
surviv
undergo
age
chang
manner
nontransfus
cell
becom
senesc
igg
detect
cell
membran
garratti
autolog
antibodi
direct
membran
antigen
normal
hidden
sialic
acid
surfac
red
cell
antibodycov
red
cell
remov
macrophag
predominantli
spleen
uncertain
whether
splenectomi
prolong
red
cell
life
span
normal
individu
two
studi
one
rabbit
one
rat
provid
conflict
result
miescher
belcher
harriss
trauma
subsequ
intern
extern
hemorrhag
anticip
unanticip
hemorrhag
surgeri
common
emerg
mani
case
amount
blood
lost
unknown
anim
withstand
loss
total
blood
volum
without
replac
follow
sudden
loss
blood
volum
take
hour
restor
lost
volum
endogen
plasma
replac
sohmer
alter
plasma
albumin
level
occur
sever
hemorrhag
level
albumin
serum
protein
decreas
increas
synthesi
albumin
begin
approxim
hour
initi
preform
albumin
move
circul
interstiti
space
malt
et
al
erythropoietin
level
begin
rise
within
hour
hct
fall
gradual
day
acut
blood
loss
linear
fall
hct
caus
logarithm
rise
erythropoietin
level
adamson
hillman
intern
hemorrhag
plasma
red
cell
reenter
circul
sever
hour
blood
bodi
caviti
initi
clot
defibrin
leav
red
cell
intact
defibrin
blood
transfus
autotransfus
bodi
caviti
histor
cadav
blood
see
cotter
volum
histori
transfus
medicin
dodd
volum
autolog
transfus
clinic
manifest
hemorrhag
shock
becom
evid
dog
blood
volum
lost
especi
dog
exercis
initi
sign
tachycardia
tachypnea
weak
puls
pale
mucou
membran
hypotens
compensatori
chang
oc
cur
increas
rate
forc
cardiac
contract
increas
oxygen
extract
tissu
dog
sudden
loss
blood
volum
fatal
time
untreat
wherea
surviv
blood
loss
blood
volum
maintain
bovin
albumin
rawson
et
al
moor
et
al
similarli
baboon
surviv
exchang
transfus
hetastarch
replac
hct
levin
et
al
studi
indic
signific
percent
age
blood
volum
lost
long
circul
volum
main
tain
bleed
occur
tissu
one
may
underestim
actual
loss
human
patient
liter
blood
commonli
lost
close
femur
fractur
liter
lost
fractur
pelvi
larg
amount
blood
may
also
lost
gastrointestin
hemor
rhage
surgic
blood
loss
may
greater
commonli
expect
exampl
seri
human
patient
undergo
meniscectomi
red
cell
volum
decreas
averag
first
week
surgeri
davi
fisher
acut
hemorrhag
arteri
pressur
maintain
longer
cardiac
output
releas
catacholamin
occur
quickli
stim
ulat
baroreceptor
aortic
arch
carotid
sinu
receptor
arteriol
skin
receptor
splanchnic
tissu
respond
norepinephrin
caus
vasoconstrict
renal
blood
flow
maintain
reflex
relax
affer
arteriol
eventu
urin
product
decreas
maintain
circu
late
volum
prolong
hypovolemia
hypotens
lead
de
creas
glomerular
filtrat
eventu
tubular
necrosi
time
circul
divert
vital
organ
heart
adren
gland
brain
low
adrenerg
receptor
acut
hemorrhag
epinephrin
caus
rapid
increas
number
neutrophil
platelet
neutrophilia
occur
mobil
margin
pool
shock
untreat
vasomotor
failur
ensu
follow
acidosi
format
microthrombosi
slow
blood
flow
factor
con
tribut
decompens
prostaglandin
endogen
opioid
capillari
obstruct
neutrophil
fibrin
capillari
perm
abil
increas
endotoxin
releas
form
damag
tissu
happen
osmot
gradient
revers
blood
volum
effect
restor
lung
interstiti
edema
interfer
alveolar
elast
impair
oxygen
may
unrespons
oxygen
therapi
chang
occur
centrilobular
hepat
necrosi
eros
small
intestin
mucosa
hypoxia
intestin
lesion
allow
loss
fluid
protein
lumen
well
entri
gramneg
bacteria
endotoxin
circul
b
fluid
support
surviv
hypovolem
shock
depend
restor
oxygen
transport
blood
volum
blood
flow
said
controversi
use
crystalloid
colloid
critic
ill
patient
emot
tenor
invers
proport
support
physiolog
data
shoemak
agre
first
approach
acut
bleed
patient
stop
bleed
restor
circul
volum
clinician
prefer
crystalloid
replac
least
initi
sever
studi
experiment
induc
hemorrhag
shock
report
improv
surviv
crystalloid
compar
colloid
collin
et
al
gaisford
et
al
although
smaller
volum
colloid
requir
like
caus
pulmonari
edema
leakag
pulmonari
tissu
vergilio
et
al
random
human
studi
experiment
primat
studi
colloid
associ
lower
incid
pulmonari
edema
rackow
et
al
gaisford
et
al
two
addit
studi
hemodynam
oxygen
transport
respons
greater
prolong
infus
colloid
nee
et
al
dawidson
et
al
colloid
improv
hemodynam
oxygen
transport
wherea
crystalloid
improv
arteri
pressur
peripher
resist
flow
oxygen
transport
clinic
situat
outcom
compar
one
random
human
studi
resuscit
time
shorter
complic
fewer
approxim
fluid
given
colloid
rest
crystalloid
shoemak
et
al
may
previous
healthi
patient
either
solut
effect
elderli
patient
underli
heart
failur
hepat
renal
insuffici
may
prudent
avoid
larg
dose
crystalloid
rackow
et
al
albumin
use
human
patient
sourc
colloid
speciesspecif
albumin
avail
anim
hetastarch
perform
well
albumin
less
antigen
although
expens
could
use
dog
cat
crystalloid
readili
avail
inexpens
free
allerg
reaction
remain
mainstay
initi
resuscit
recent
use
hyperton
salin
evalu
rocha
et
al
advantag
isoton
crystalloid
small
volum
hyperton
salin
quickli
draw
fluid
interstiti
space
restor
circul
volum
follow
addit
support
need
replac
volum
crystalloid
equal
volm
blood
remov
restor
blood
volum
canin
felin
patient
commonli
use
initi
dose
ringer
lactat
dog
mlkg
first
hour
mlkg
cat
repres
replac
one
blood
volum
breznock
strack
adequaci
treatment
determin
overal
clinic
appear
patient
heart
respiratori
rate
mucou
membran
color
capillari
refil
time
puls
qualiti
hct
urin
output
sometim
supplement
serial
measur
arteri
central
venou
pressur
special
center
pulmonari
wedg
pressur
paramet
alway
correl
well
predictor
surviv
shoemak
et
al
addit
evalu
may
made
abil
circulatori
system
accept
larg
rapid
infus
fluid
without
produc
pulmonari
edema
assum
hypovolemia
associ
normal
venou
complianc
complet
descript
treatment
monitor
techniqu
human
dog
cat
provid
shoemak
hartsfield
valuabl
indic
respons
restor
oxygen
transport
tissu
perfus
therapeut
goal
rais
mean
arteri
pressur
maintain
central
venou
pressur
cm
h
avoid
pulmonari
edema
maintain
normal
urin
output
blood
gase
heart
rate
hct
monitor
fluid
replac
imprecis
massiv
hemorrhag
caus
death
minim
drop
overhydr
lower
hct
lead
fals
sens
urgenc
red
cell
replac
decis
whether
red
cell
need
base
upon
combin
known
estim
blood
loss
respons
initi
fluid
resuscit
hct
total
serum
protein
level
c
blood
transfus
assum
initi
attempt
resuscit
crystalloid
colloid
replac
unsuccess
red
cell
must
replac
histor
physician
veterinarian
reli
upon
fresh
store
whole
blood
replac
loss
first
thought
seem
logic
blood
loss
replac
whole
blood
initi
blood
replac
consist
prbc
movement
albumin
interstiti
space
capillari
replac
lost
blood
volum
without
need
supplementari
plasma
addit
prbc
less
adenin
citrat
sodium
ammonia
histocompat
antigen
antibodi
whole
blood
pack
red
cell
also
activ
increas
plasma
volum
blood
remov
dog
equalvolum
replac
use
prbc
given
one
group
plasma
given
group
red
cell
caus
movement
interstiti
plasma
circul
result
equal
increas
plasma
volum
group
valeri
et
al
valeri
altschul
describ
miss
blood
syndrom
soldier
suscit
crystalloid
colloid
blood
product
patient
chronic
hypovolemia
detect
measur
hct
blood
pressur
larg
volum
transfus
red
cell
requir
rais
plasma
volum
reexpand
peripher
circul
rapid
transfus
necessari
lifethreaten
hemorrhag
shock
largebor
needl
use
posit
pressur
achiev
wrap
blood
pressur
cuff
around
bag
blow
cuff
hct
prbc
approxim
salin
ad
achiev
rapid
flow
fluid
salin
mix
blood
amount
blood
given
depend
upon
amount
blood
lost
patient
respons
initi
dose
mlkg
prbc
given
patient
reassess
larg
volum
fluid
prbc
given
one
must
watch
sign
volum
overload
distend
pulsat
jugular
vein
increas
central
venou
pre
sure
pulmonari
edema
case
requir
massiv
transfusiondefin
administr
total
estim
blood
volum
red
cell
within
hoursloss
clot
factor
platelet
effect
red
cell
storag
lesion
oxygen
deliveri
must
consid
larg
reserv
platelet
present
spleen
normal
individu
releas
time
increas
need
common
platelet
count
increas
moder
hemorrhag
human
platelet
count
gener
remain
transfus
unit
store
blood
platelet
present
either
store
whole
blood
prbc
count
et
al
drop
platelet
count
occur
larg
volum
fluid
prbc
dilut
platelet
replac
indic
abnorm
bleed
occur
count
low
fluid
shift
reestablish
equilibrium
increas
platelet
count
serum
protein
occur
decreas
platelet
count
moder
hemorrhag
transfus
might
indic
presenc
diffus
intravascular
coagul
dic
underli
diseas
clot
factor
deplet
may
occur
massiv
transfus
prbc
may
requir
replac
either
freshfrozen
plasma
ffp
fresh
whole
blood
advantag
store
whole
blood
prbc
treatment
acut
hemorrhag
patient
receiv
transfus
equival
one
blood
volum
retain
approxim
origin
blood
element
even
without
addit
consumpt
clot
factor
occur
hemorrhag
begin
approach
level
coagul
becom
impair
sohmer
scott
patient
receiv
larg
volum
prbc
may
develop
decreas
level
clot
factor
likelihood
sever
deplet
low
coagul
normal
hemorrhag
normal
individu
circul
level
clot
factor
excess
need
addit
extra
vascular
distribut
factor
present
except
factor
v
viii
fibrinogen
factor
roughli
size
albumin
share
intravascular
extravascular
distribut
count
pool
factor
viii
bound
vascular
endothelium
releas
stress
stimul
wall
et
al
difficult
predict
whether
replac
clot
factor
need
massiv
transfus
monitor
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
least
activ
clot
time
act
use
determin
need
efficaci
replac
transfus
larg
volum
cold
blood
extract
energi
patient
heat
product
hypothermia
also
interfer
platelet
function
inhibit
thromboxan
b
product
decreas
oxygen
releas
tissu
interfer
metabol
citrat
valeri
et
al
reduct
bleed
time
correl
well
warm
patient
indic
platelet
function
defect
revers
situat
massiv
transfus
store
prbc
whole
blood
storag
lesion
decreas
ph
atp
may
interfer
oxygen
deliveri
red
cell
surviv
metabol
citrat
bicarbon
tend
neutral
drop
ph
although
regener
byproduct
transfus
clear
place
increas
burden
patient
ideal
posit
demand
patient
undergo
massiv
transfus
greatest
risk
suffer
advers
effect
transfus
practic
outlin
manag
human
patient
hemorrhag
shock
outlin
crystalloid
colloid
infus
follow
prbc
sohmer
scott
depend
upon
pt
aptt
platelet
count
ffp
platelet
ad
occasion
cryoprecipit
may
need
bleed
continu
fibrinogen
level
remain
low
despit
ffp
administr
signific
bleed
like
unless
pt
aptt
least
time
control
veterinarian
advantag
abl
give
fresh
whole
blood
need
requir
test
human
blood
diseasecaus
organ
fresh
whole
blood
readili
avail
major
indic
fresh
whole
blood
patient
need
red
cell
clot
factor
platelet
patient
massiv
hemorrhag
bleed
sever
liver
diseas
dic
thrombocytopenia
discuss
section
ii
prbc
indic
first
addit
oxygencarri
capac
need
histor
anesthesiologist
surgeon
felt
hct
hemoglobin
gmdl
requir
human
undergo
surgic
procedur
requir
gener
anesthesia
levin
et
al
level
compensatori
mechan
place
anemia
present
day
coronari
vessel
maxim
dilat
cardiac
output
increas
pulmonari
cardiac
function
normal
hct
even
less
might
accept
patient
anesthesia
activ
requir
concern
moor
mollison
et
al
transfus
need
surgic
patient
emerg
better
given
near
end
procedur
allow
maximum
conserv
transfus
cell
see
dodd
volum
autolog
transfus
discuss
intraop
salvag
method
minim
need
homolog
blood
make
use
immedi
avail
safe
suppli
autolog
blood
hemolysi
abnorm
shorten
red
cell
life
span
beyond
abil
marrow
compens
may
caus
intrins
red
cell
defect
exogen
effect
substanc
plasma
exampl
intrins
defect
includ
inherit
red
cell
enzym
abnorm
pyruv
kinas
defici
basenji
beagl
dog
phosphofructokinas
defici
english
springer
spaniel
hemoglobinopathi
sickl
cell
anemia
thalassemia
common
caus
chronic
hemolyt
anemia
man
hemoglobinopathi
report
anim
congenit
erythropoiet
porphyria
occur
rare
cattl
cat
pig
usual
associ
signific
anemia
compat
red
cell
transfus
given
dog
intrins
red
cell
disord
surviv
transfus
cell
normal
hemolysi
exogen
caus
much
common
man
anim
caus
intrins
red
cell
defect
exogen
caus
includ
infecti
agent
antibodi
toxin
transfus
cell
destroy
readili
recipi
cell
case
hemolyt
anemia
exogen
caus
provid
caus
still
present
oldest
cell
donor
blood
suscept
hemolysi
wherea
reticulocyt
resist
rate
destruct
transfus
cell
also
increas
presenc
alloantibodi
immunemedi
hemolyt
anemia
common
problem
encount
veterinari
clinician
acut
fulmin
immunemedi
hemolyt
anemia
imha
one
common
caus
anemia
dog
occur
equal
sex
male
risk
year
age
femal
switzer
jain
poodl
cocker
spaniel
old
english
sheep
dog
may
higher
preval
overal
death
rate
approxim
complic
imha
includ
cardiac
hepat
renal
failur
hemoglobinemia
hemoglobinuria
icteru
pulmonari
thromboembol
dic
klein
et
al
dat
posit
spontan
autoagglutin
note
immedi
blood
drawn
dog
autoagglutin
intravascular
hemolysi
igg
plu
complement
red
cell
slappendel
mortal
form
quit
high
dog
imha
almost
sever
form
requir
one
transfus
addit
immunosuppress
therapi
strongli
dat
posit
autoagglutin
difficult
imposs
type
cross
match
patient
may
serolog
incompat
red
cell
donor
previous
transfus
may
also
alloantibodi
may
imposs
detect
sometim
difficulti
type
human
patient
posit
control
overcom
incub
patient
red
cell
minut
wash
temperatur
may
elut
antibodi
allow
type
proceed
must
done
cautious
prevent
hemolysi
petz
procedur
evalu
dog
destruct
transfus
cell
may
also
increas
presenc
fever
splenomegali
possibl
increas
activ
mononuclear
phagocyt
although
true
rapid
hemolysi
transfus
red
cell
add
morbid
hypoxia
sever
anemia
may
contribut
even
damag
heart
liver
kidney
thu
transfus
withheld
lifethreaten
imha
decis
transfus
must
made
individu
basi
use
clinic
paramet
simpli
hct
decid
serial
determin
hct
help
determin
rate
progress
stabil
diseas
transfus
need
human
canin
patient
toler
seemingli
incompat
red
cell
infrequ
reaction
surviv
transfus
cell
equal
patient
cell
net
result
transfus
provid
least
temporari
benefit
rare
sever
imha
transfus
cell
destroy
rapidli
petz
human
patient
imha
specif
autoantibodi
sometim
determin
elut
techniqu
test
antibodi
red
cell
known
phenotyp
dog
practic
ident
canin
autoantibodi
remain
unknown
human
patient
slightli
smaller
percentag
dog
warmantibodi
imha
respond
immunosuppress
dose
corticosteroid
first
day
although
hct
may
reach
normal
level
week
later
dog
fail
respond
corticosteroid
may
respond
stronger
immunosuppress
drug
cyclophosphamid
azathiaprin
ad
b
caus
hemolyt
anemia
tabl
list
caus
hemolyt
anemia
anim
gener
approach
treatment
remov
caus
possibl
drug
current
given
consid
suspect
known
caus
hemolysi
must
discontinu
along
other
essenti
semimoist
cat
food
contain
propylen
glycol
shorten
red
cell
life
span
fed
anem
cat
transfus
requir
treatment
hemolyt
anemia
caus
approach
imha
discuss
specif
therapi
underli
caus
beyond
scope
articl
limit
factor
continu
erythropoiesi
iron
small
amount
blood
lost
period
time
marrow
respond
initi
reticulocytosi
hct
remain
normal
depend
quantiti
iron
store
microcyt
hypochrom
anemia
eventu
develop
neonat
anim
low
iron
store
becom
defici
diet
inadequ
even
absenc
hemorrhag
older
anim
adequ
store
resist
iron
defici
usual
indic
chronic
blood
loss
occur
occult
blood
loss
occur
frequent
via
gastrointestin
tract
bloodsuck
parasit
ulcer
tumor
caus
blood
loss
identifi
remov
patient
stabl
iron
replac
may
prevent
need
transfus
anemia
sever
especi
loss
anticip
transfus
prbc
indic
one
sourc
chronic
blood
loss
human
anim
patient
iatrogen
repeat
blood
sampl
hospit
human
patient
report
patient
transfus
one
unit
blood
drawn
diagnost
test
smoller
kruskal
also
problem
small
dog
cat
draw
blood
repeat
basi
keep
hct
mind
rememb
less
blood
need
drawn
anem
patient
obtain
need
volum
plasma
serum
anemia
secondari
decreas
product
commonli
associ
primari
bone
marrow
diseas
pure
red
cell
aplasia
aplast
anemia
myelodysplasia
hematopoiet
malign
retrovir
infect
caus
includ
decreas
erythropoietin
chronic
renal
diseas
iron
defici
immunemedi
destruct
red
cell
precursor
anemia
chronic
diseas
anemia
chronic
diseas
may
common
form
anemia
seen
hospit
human
anim
patient
anemia
gener
mild
often
comment
upon
pathogenesi
includ
shorten
red
cell
life
span
hyperact
reticuloendotheli
system
addit
mobil
iron
store
decreas
marrow
fail
increas
product
compens
loss
cat
especi
prone
anemia
chronic
diseas
normal
short
red
cell
life
span
small
blood
volum
bodi
weight
ratio
compar
speci
breznock
strack
addit
mani
cat
variou
ill
carri
retrovirus
felin
leukemia
immunodefici
virus
suppress
marrow
anemia
chronic
diseas
usual
requir
specif
therapi
resolv
underli
diseas
correct
sever
nonregen
anemia
attribut
anemia
chronic
diseas
probabl
anoth
caus
decreas
red
cell
product
anemia
slowli
progress
may
quit
sever
clinic
sign
becom
evid
although
compensatori
mechan
allow
patient
function
low
hct
period
transfus
prbc
may
requir
surviv
contrast
anemia
caus
hemolysi
blood
loss
anemia
lack
product
gener
poorer
prognosi
recoveri
evalu
bone
marrow
may
provid
clue
diagnosi
well
prognosi
clinic
sign
anemia
tachycardia
tachypnea
weak
present
rest
transfus
indic
patient
asymptomat
transfus
may
withheld
howev
hct
drop
anim
signific
risk
acut
collaps
becom
stress
hct
anim
rare
rais
normal
rang
transfus
one
need
concern
transfus
suppress
hematopoiesi
also
hemosiderosi
iron
overload
becom
possibl
multipl
transfus
addit
iron
supplement
avoid
cross
match
becom
progress
import
anim
receiv
multipl
transfus
risk
sensit
greater
advanc
product
use
genet
engin
hematopoiet
growth
factor
discuss
donahu
volum
dog
cat
anemia
secondari
chronic
renal
failur
often
respond
treatment
recombin
human
erythropoietin
cowgil
et
al
militari
personnel
treat
plasma
world
war
ii
treatment
hemorrhag
shock
pack
red
cell
obtain
byproduct
recogn
valuabl
resourc
time
later
learn
valu
crystalloid
colloid
risk
associ
plasma
use
volum
expand
declin
confer
nation
institut
health
conclud
justif
use
plasma
volum
expand
nutrit
supplement
although
approxim
freshfrozen
plasma
transfus
human
hospit
given
reason
defin
american
associ
blood
bank
aabb
standard
widmann
ffp
separ
fresh
whole
blood
centrifug
frozen
within
hour
collect
see
authement
volum
major
use
ffp
anim
man
sourc
clot
factor
reason
canin
ffp
transfus
categor
tuft
univers
school
veterinari
medicin
common
use
treatment
dic
stone
et
al
dog
normal
short
clot
time
compar
man
seem
especi
prone
develop
dic
secondari
mani
seriou
ill
common
caus
dic
includ
hemangiosarcoma
malign
immunemedi
hemolyt
anemia
gastric
torsion
pancreat
heat
stroke
liver
diseas
infect
similar
report
previous
feldman
et
al
laboratori
diagnosi
dic
overemphas
may
confus
westphal
test
may
chang
rapidli
classic
pictur
low
platelet
fibrinogen
prolong
pt
ptt
elev
fibrinogen
degrad
product
fdp
level
may
present
whenev
fibrinogen
level
decreas
mgdl
pt
ptt
prolong
fibrinogen
need
fibrin
format
test
one
studi
dog
factor
v
deplet
factor
viii
feldman
et
al
although
differ
report
human
experiment
studi
dog
chang
approach
treatment
rabin
friedman
thrombocytopenia
consist
diagnosi
dic
certain
without
platelet
count
return
normal
slowli
sever
day
dic
resolv
fibrinogen
level
howev
rapidli
return
normal
fdp
clear
primarili
kupffer
cell
liver
excret
urin
elev
fdp
may
sometim
seen
hepat
renal
failur
westphal
discuss
treatment
dic
gener
much
emot
discuss
crystalloid
versu
colloid
treatment
shock
time
dic
clinic
evid
clot
factor
sever
deplet
patient
bleed
fibrinogen
low
pt
ptt
prolong
replac
clot
factor
ffp
need
addit
support
care
burn
withhold
ffp
presenc
signific
ongo
hemorrhag
much
like
old
argument
nutrit
support
withheld
cancer
patient
feed
tumor
cell
addit
coagul
factor
ffp
contain
antithrombin
iii
iii
potent
inhibitor
thrombin
format
replac
iii
help
prevent
thrombosi
endogen
product
iii
dog
shown
increas
rapidli
begin
within
hour
induct
dic
endotoxin
inject
tanaka
et
al
product
abl
surpass
consumpt
day
despit
ongo
dic
one
elimin
underli
caus
dic
bleed
evid
necessari
treat
laboratori
abnorm
simpli
monitor
along
patient
sever
case
dic
excess
blood
loss
replac
red
cell
clot
factor
plate
let
may
need
fresh
whole
blood
indic
initi
individu
compon
ad
later
need
exampl
sever
deplet
fibrinogen
might
best
treat
supplementari
cryoprecipit
heparin
sometim
use
conjunct
ffp
controversi
exist
use
gener
agreement
heparin
use
alon
bleed
patient
riski
unlik
success
heparin
specif
activ
iii
requir
presenc
anticoagul
effect
patient
continu
bleed
show
evid
thrombosi
hour
ther
api
begun
underli
diseas
clot
factor
replac
heparin
ad
except
rule
would
appli
case
risk
develop
dic
high
exampl
dog
sever
heat
stroke
frequent
develop
dic
might
benefit
prophylact
heparin
thrombosi
begin
coagul
defect
yet
measur
recommend
dose
heparin
vari
unitskg
everi
hour
bick
unitskg
intraven
subcutan
everi
hour
ruehl
et
al
gener
smaller
dose
pre
fer
westphal
despit
controversi
heparin
never
shown
increas
surviv
gramneg
sepsi
state
dic
encount
corrigan
jordan
harker
argu
heparin
aggrav
bleed
result
rise
fibrinogen
level
reflect
defect
fibrin
stabil
improv
hemostasi
advoc
incub
heparin
ffp
administ
activ
antithrombin
iii
help
prevent
thrombosi
ruehl
etal
therapeut
agent
inhib
itor
fibrinolysi
acid
steroid
like
help
may
danger
steroid
slow
clearanc
fdp
bac
teria
immun
complex
may
indic
spetic
shock
gramneg
bacteria
antithrombin
iii
concentr
recent
use
success
human
patient
avail
anim
thought
review
topic
feinstein
stress
beyond
identif
remov
underli
caus
treatment
dic
must
individu
gener
difficult
patient
activ
bleed
requir
surgeri
factor
replac
receiv
heparin
hepat
failur
product
clot
factor
especi
vita
min
kdepend
factor
decreas
ascit
edema
present
effect
ffp
less
factor
diffus
fluid
vitamin
k
may
benefit
patient
ffp
use
treatment
hemophilia
von
willebrand
diseas
although
cryoprecipit
avail
appropri
patient
unless
bleed
extens
advantag
avoid
transfus
red
cell
prevent
delay
develop
alloantibodi
could
interfer
futur
transfus
frozen
plasma
fp
defin
salvag
whole
blood
store
refriger
longer
hour
freez
ffp
store
year
frozen
plasma
may
use
sourc
stabl
clot
factor
vitamin
kdepend
factor
ii
vii
ix
x
frozen
plasma
contain
therapeut
level
unstabl
factor
viii
v
use
fp
includ
acut
sever
warfarin
toxic
hemophilia
b
plasma
sometim
use
anim
sourc
albumin
speciesspecif
albumin
solut
avail
plasma
remov
normal
dog
replac
crystalloid
hypoalbuminem
edema
develop
plasma
dilut
period
cervera
moss
albumin
difficult
suppli
adequ
amount
revers
hypoalbuminemia
approxim
total
bodi
albumin
locat
interstiti
space
concentr
equilibrium
plasma
hypoalbuminemia
develop
calcul
plasma
albumin
deficit
repres
wholebodi
deficit
albumin
lost
via
kidney
gastrointestin
tract
albumin
suppli
transfus
quickli
lost
acut
revers
hypoalbuminemia
might
occur
burn
might
respond
well
plasma
transfus
otherwis
hypoproteinemia
better
treat
parenter
enter
aliment
nutrit
support
catabol
state
infus
albumin
metabol
calori
sourc
addit
sodium
contain
plasma
might
also
aggrav
edema
ascit
cryoprecipit
concentr
solut
factor
viii
vwf
fibrinogen
fibronectin
prepar
ffp
slow
thaw
separ
cryopoor
plasma
cryoprecipit
use
primarili
treat
hemophilia
von
willebrand
diseas
vwd
bleed
must
stop
soon
possibl
anim
conserv
red
cell
also
minim
damag
joint
approach
treatment
hemophilia
vwd
includ
vasopressin
ddavp
danazol
testosteron
deriv
efficaci
increas
level
factor
viii
vwf
thyroid
hormon
also
help
decreas
bleed
episod
dog
vwd
approach
describ
detail
dodd
volum
blood
substitut
obvious
drug
inhibit
platelet
function
especi
aspirin
avoid
patient
coagulopathi
although
hypofibrinogenemia
occur
dic
specif
replac
fibrinogen
usual
need
adequ
amount
suppli
ffp
cryoprecipit
use
human
surgeri
sourc
tissu
glue
dog
plasma
given
without
concern
blood
type
red
cell
present
plasma
donor
unlik
preform
antibodi
previous
transfus
plasma
separ
prbc
major
citrat
remain
plasma
gener
given
hour
period
dose
depend
degre
clot
factor
deficit
preand
posttransfus
evalu
pt
aptt
indic
appropri
start
dose
unit
per
kg
cryoprecipit
ffp
given
prior
surgeri
infus
begin
hour
anesthesia
maximum
benefit
exampl
factor
viii
halflif
hour
minim
benefit
obtain
give
sever
hour
surgeri
major
indic
platelet
transfus
stop
bleed
patient
decreas
platelet
product
function
platelet
transfus
given
less
frequent
anim
man
difficulti
prepar
need
volum
storag
time
short
essenti
function
platelet
present
store
refriger
whole
blood
pack
red
cell
even
fresh
whole
blood
contain
adequ
platelet
volum
commonli
transfus
rais
platelet
count
thrombocytopen
anim
human
patient
standard
platelet
transfus
contain
platelet
concentr
unit
blood
store
plateletrich
plasma
day
room
temperatur
constant
rock
prevent
aggreg
platelet
pack
unit
expect
rais
platelet
count
adult
human
recipi
approxim
imm
diat
transfus
thu
dog
receiv
unit
fresh
whole
blood
plateletrich
plasma
would
expect
increas
approxim
unit
per
kg
estab
lish
reason
start
dose
unit
given
depend
ing
posttransfus
count
clinic
statu
patient
practic
approach
bleed
thrombocytopen
anim
suppli
least
platelet
fresh
whole
blood
red
cell
replac
ad
benefit
increas
platelettoplatelet
platelettoendothelium
interact
thu
bleed
time
may
improv
thrombocytopen
patient
red
cell
transfus
escolar
et
al
patient
platelet
count
toler
sur
geri
without
need
platelet
tomasulo
lene
unexpect
bleed
occur
platelet
given
need
seldom
urgent
bleed
thrombocytopenia
rapid
bleed
sever
may
indic
inadequ
surgic
hemostasi
rather
effect
thrombocytopenia
platelet
transfus
con
sider
urgent
bleed
central
nervou
system
eye
platelet
transfus
may
ineffect
presenc
splenomeg
ali
sepsi
dic
hypothermia
advers
effect
local
system
hypothermia
platelet
func
tion
often
overlook
blood
coagul
reaction
enzymat
depend
temperatur
cool
skin
caus
rever
ibl
platelet
dysfunct
prolong
bleed
time
valeri
et
al
presenc
idiopath
thrombocytopen
purpura
itp
alloimmun
previou
transfus
platelet
transfus
may
total
ineffect
human
hlamatch
platelet
obtain
apheresi
use
patient
develop
alloantibodi
platelet
transfus
frequent
ineffect
even
nonimmun
host
tomasulo
lene
dog
use
model
studi
platelet
function
surviv
one
studi
dog
given
eight
platelet
transfus
singl
unrel
donor
becom
immun
averag
transfus
slichter
et
al
alloimmun
result
rapid
destruct
tran
fuse
platelet
could
prevent
pretreat
prednison
splenectomi
cyclophosphamid
vincristin
studi
emphas
highli
immunogen
natur
platelet
transfus
import
posttransfus
monitor
situat
platelet
destruct
itp
surviv
transfus
platelet
matter
minut
rather
day
may
condit
marrow
failur
spleen
major
loss
platelet
occur
imprud
assum
platelet
transfus
administ
benefit
patient
platelet
count
run
within
hour
transfus
count
rise
expect
destruct
platelet
may
occur
platelet
transfus
result
increas
platelet
count
immedi
transfus
consid
failur
tomasulo
lene
anim
studi
shown
increment
necessari
bleed
time
shorten
roy
djerassi
techniqu
develop
freez
human
canin
platelet
dimethyl
sulfoxid
melaragno
et
al
valeri
et
al
technolog
appli
speci
current
done
research
purpos
granulocyt
transfus
popular
treat
human
patient
sepsi
neutropenia
new
improvedspectrum
antibiot
develop
use
granulocyt
transfus
declin
addit
reason
declin
difficulti
collect
adequ
number
cell
daili
patient
neutrophil
normal
total
replac
least
twice
daili
larg
number
least
x
day
must
given
mollison
et
al
moreov
alloimmun
occur
rapidli
even
previou
whole
blood
transfus
pulmonari
toxic
sequestr
cell
lung
problem
westrick
et
al
benefit
granulocyt
transfus
occur
septic
newborn
infant
transfus
still
use
situat
veterinari
medicin
use
made
septic
newborn
foal
otherwis
use
anim
restrict
research
protocol
discuss
white
cell
transfus
see
weiss
volum
transfus
blood
compon
gener
safe
procedur
anim
particularli
dog
cat
discuss
primarili
concern
speci
time
onset
side
effect
transfus
vari
immedi
cat
receiv
littl
ml
incompat
blood
delay
year
transfusiontransmit
retrovir
diseas
sever
reaction
vari
mild
transient
pyrexia
death
reaction
prevent
risk
benefit
must
weigh
situat
transfus
consid
increas
concern
danger
human
transfus
especi
concern
viru
transmiss
increas
emphasi
place
develop
safe
effect
altern
blood
hemolyt
reaction
one
think
transfus
reaction
usual
come
mind
acut
intravascular
hemolyt
catastroph
might
occur
aboincompat
human
transfus
fortun
veterinari
medicin
reaction
rare
low
preval
natur
occur
isoantibodi
group
b
cat
except
like
strong
antia
antibodi
group
red
cell
given
group
b
cat
cell
destroy
within
minut
cat
may
also
experi
acut
complementmedi
shocklik
reaction
dog
clinic
signific
natur
occur
isoantibodi
problem
antibodi
develop
persist
initi
transfus
becom
problem
second
transfus
given
contain
antigen
sign
acut
hemolyt
reaction
incompat
red
cell
includ
acut
fever
tachycardia
weak
tremor
vomit
collaps
sign
occur
transfus
stop
line
kept
open
salin
blood
sampl
drawn
edta
portion
spun
capillari
tube
check
hemoglobinemia
posit
dat
also
seen
transfus
cell
destroy
could
neg
recipi
blood
sampl
remain
donor
blood
bag
save
test
immunolog
incompat
bacteriolog
evalu
gram
stain
cultur
intravascular
hemolysi
occur
potenti
acut
renal
failur
exist
free
hemoglobin
thought
caus
renal
damag
antibodyco
red
cell
stroma
known
caus
renal
vasoconstrict
ischemia
littl
g
stroma
incompat
red
cell
induc
renal
failur
schmidt
holland
dog
transfus
even
autolog
hemolyz
red
cell
lead
decreas
factor
x
viii
fibrinogen
pulmonari
arteri
thrombosi
rabin
friedman
presum
thromboplast
substanc
red
cell
membran
stroma
respons
shinowara
antigenantibodi
complex
decreas
blood
pressur
complement
serotonin
histamin
predispos
develop
dic
clearli
recognit
acut
hemolyt
transfus
reaction
call
immedi
action
repetit
lab
test
monitor
major
aim
treatment
maintain
blood
pressur
renal
blood
flow
prevent
dic
fluid
therapi
supplement
furosemid
osmot
diuret
mannitol
also
use
increas
urin
output
significantli
increas
renal
blood
flow
peschel
pressor
agent
need
dopamin
hydrochlorid
effect
dilat
renal
vasculatur
increas
cardiac
output
risk
dic
high
prophylact
heparin
given
immedi
initi
load
dose
continu
approxim
hour
heparin
contraind
underli
reason
transfus
pertain
trauma
surgeri
hemorrhag
particularli
difficult
problem
acut
hemolyt
reaction
patient
anesthesia
wherein
sign
might
unexpect
hypotens
increas
capillari
ooz
blood
reaction
suspect
workup
awak
patient
although
hemolyt
reaction
seriou
also
rare
reaction
prevent
pretransfus
test
common
reason
human
acut
hemolyt
reaction
administr
error
mixup
patient
identif
rather
laboratori
error
evid
pretreat
recipi
antihistamin
steroid
prevent
suppress
hemolyt
transfus
reaction
schmidt
red
cell
transfus
sensit
individu
sensit
occur
first
transfus
common
reaction
delay
hemolysi
delay
reaction
hemolysi
may
occur
day
week
later
antibodi
produc
occur
frequent
previous
transfus
patient
develop
antibodi
titer
low
detect
cross
match
transfus
initi
secondari
immun
respons
rapid
rise
antibodi
may
subclin
notic
unless
transfus
cell
label
surviv
measur
destruct
rapid
icteru
may
develop
benefici
effect
transfus
shorten
dat
check
whenev
drop
hct
rapid
expect
antibodyco
transfus
cell
posit
effect
difficult
appreci
patient
transfus
treatment
immunemedi
hemolyt
anemia
patient
datposit
pretransfus
often
destroy
transfus
cell
rapidli
antibodi
may
detect
patient
serum
absorb
onto
red
cell
typic
antibodi
becom
detect
peak
level
day
transfus
mollison
et
al
hemolyt
reaction
occur
nonimmunolog
caus
blood
hemolyz
prior
transfus
caus
includ
overh
freez
refriger
temperatur
drop
low
mix
hypoton
solut
dextros
water
mechan
trauma
red
cell
draw
administr
blood
contamin
hemolyt
bacteria
peschel
develop
fever
transfus
could
indic
bacteri
contamin
blood
howev
rare
blood
contamin
reaction
recipi
usual
immedi
sever
addit
fever
trembl
acut
collaps
usual
occur
reaction
occur
transfus
stop
immedi
remain
content
bag
gram
stain
cultur
intraven
antibiot
treatment
shock
institut
immedi
febril
reaction
mild
relat
infect
previous
transfus
anim
becom
sensit
histocompat
antigen
donor
react
fever
transfus
despit
fever
patient
usual
clinic
better
transfus
sometim
sever
anem
cat
present
hospit
normal
subnorm
temperatur
develop
fever
hour
transfus
cat
fever
caus
underli
diseas
becom
evid
cat
condit
improv
transfus
fever
develop
transfus
patient
appear
stabl
improv
often
advantag
monitor
without
treatment
hour
nonspecif
transfusioninduc
fever
often
spontan
resolv
within
time
allerg
reaction
rare
seen
canin
human
patient
speci
common
manifest
urticaria
angioneurot
edema
caus
probabl
donor
plasma
antigen
recipi
sensit
one
reason
donor
receiv
medic
time
donat
seri
atop
human
patient
known
sensit
common
allergen
pollen
dust
milk
egg
transfus
pool
serum
almost
alway
follow
moder
sever
urticaria
wherea
normal
subject
rare
reaction
maunsel
allerg
reaction
occur
transfus
stop
intraven
antihistamin
diphenhydramin
given
reaction
sever
sign
laryng
bronchopulmonari
involv
corticosteroid
even
epinephrin
ml
solut
intraven
dog
cat
given
well
typic
reaction
mild
subsid
quickli
case
transfus
may
continu
argu
danger
continu
deliv
prove
allergen
clinic
report
support
content
circulatori
overload
like
occur
cat
small
dog
larg
volum
blood
given
normovolem
patient
standard
volum
given
anim
underli
cardiac
insuffici
anem
anim
suscept
circulatori
overload
alway
receiv
slowli
infus
prbc
whole
blood
chronic
anem
anim
risk
cardiac
hypertrophi
dilat
often
present
longterm
increas
cardiac
output
time
anim
requir
transfus
cardiac
compensatori
mechan
alreadi
stress
maxim
addit
blood
volum
may
produc
pulmonari
edema
sign
includ
cough
cyanosi
dyspnea
moist
lung
sound
overload
suspect
transfus
stop
furosemid
oxygen
administ
citrat
ideal
anticoagul
standpoint
safeti
metabol
liver
within
minut
administr
experiment
citrat
toxic
hard
produc
equival
dose
citrat
liter
citrat
blood
given
without
reaction
adult
man
minut
nakason
et
al
toxic
chang
produc
dog
sign
includ
ekg
chang
prolong
qt
pulsu
alternan
depress
p
wave
muscl
tremor
occur
well
addit
dose
given
ventricular
fibril
occur
diagnosi
made
measur
serum
calcium
ioniz
fraction
decreas
anim
portosystem
shunt
sever
liver
diseas
hypothermia
metabol
citrat
slowli
normal
prone
toxic
compon
citrat
ffp
prp
whole
blood
pack
red
cell
low
citrat
unlik
caus
toxic
case
citrat
toxic
revers
transfus
stop
minut
restart
lower
rate
inject
calcium
glucon
revers
effect
rare
need
alkalin
byproduct
citrat
metabol
offset
acidosi
induc
store
blood
collin
et
al
acidosi
rare
transfus
store
blood
potassium
toxic
primarili
concern
human
hors
receiv
store
blood
anim
hors
potassium
con
centrat
red
cell
equal
plasma
hyperkalemia
concern
even
man
clinic
signific
hyperkalemia
rare
occur
less
frequent
hypokalemia
increas
potassium
predi
pose
citrat
toxic
potassium
citrat
advers
affect
cardiac
rhythm
function
ammonia
level
rise
store
blood
may
caus
problem
patient
liver
failur
much
written
danger
pulmonari
function
caus
microaggreg
massiv
transfus
consist
platelet
white
cell
red
cell
stromal
debri
increas
first
week
storag
remov
use
filter
recent
clinic
studi
indic
problem
microaggreg
overemphas
seldon
routin
use
millipor
filter
unnecessari
may
detriment
rapid
transfu
sion
deliv
small
filter
hemosiderosi
rare
complic
occur
patient
receiv
numer
transfus
bleed
pack
red
cell
contain
mg
feml
normal
daili
excret
iron
bodi
mg
initi
excess
iron
store
reticuloendotheli
cell
caus
clinic
sign
transferrin
satur
addit
iron
store
hepat
parenchym
cell
may
damag
liver
marcu
huehn
anim
receiv
multipl
transfus
hematin
therapi
avoid
anim
transfus
unless
iron
defici
present
immunolog
effect
transfus
limit
alloimmun
recipi
first
suspicion
transfus
might
immunosuppress
relat
observ
improv
renal
allograft
surviv
transfus
patient
opelz
terasaki
recent
human
cancer
patient
transfus
time
tumor
resect
shorter
surviv
time
patient
stage
diseas
transfus
blumberg
heal
addit
patient
receiv
whole
blood
wors
receiv
pack
red
cell
suggest
plasma
contain
histocompat
antigen
antiidiotyp
antibodi
immunoregulatori
substanc
could
caus
immunosuppress
anim
model
blood
transfus
tumor
recurr
plasma
compon
associ
highest
rate
tumor
growth
horimi
et
al
addit
immun
suppress
transfus
especi
store
red
cell
thought
caus
reticuloendotheli
blockad
fix
macrophag
spleen
liver
engulf
red
cell
unabl
phagocyt
organ
phenomenon
like
clinic
signific
human
death
caus
transfus
result
transmiss
infecti
diseas
exampl
transfusiontransmit
infect
includ
aid
htlvi
infect
hepat
malaria
babesiosi
chaga
diseas
cytomegaloviru
epsteinbarr
viru
infect
syphili
rare
infect
brucellosi
salmonellosi
toxoplasmosi
trypanosomiasi
filariasi
agent
share
common
properti
prolong
persist
blood
healthi
carrier
long
incub
period
stabil
store
blood
ideal
test
done
agent
accur
test
avail
carrier
detect
relat
organ
expect
transmit
anim
anim
transfus
retro
virus
major
import
cat
cattl
hors
cat
risk
random
cat
carri
either
felin
leukemia
viru
felin
immunodefici
viru
although
hors
cattl
less
frequent
transfus
dog
cat
bovin
leukemia
viru
equin
anemia
viru
rel
preval
depend
geograph
preval
diseas
dog
risk
transfus
transmit
babesiosi
ehrlichiosi
microfilari
stage
dirofilariasi
addit
retro
virus
cat
may
carri
corona
viru
caus
felin
infecti
periton
although
transmiss
blood
prove
hemobartonellosi
anoth
diseas
increas
risk
transfus
cat
use
apheresi
obtain
singledonor
platelet
plasma
administr
patient
describ
authement
volum
procedur
also
use
remov
abnorm
compon
blood
either
cell
plasma
exampl
clinic
indic
remov
larg
number
blast
acut
leukemia
leukopheresi
excess
red
cell
polycythemia
vera
abnorm
antibodi
lipid
protein
plasmapheresi
excess
platelet
thrombocythemia
plateletpheresi
sever
machin
avail
collect
desir
compon
continuousflow
separ
centrifug
filtrat
effici
rapid
process
larg
volum
blood
extracorpori
volum
rel
larg
machin
readili
adapt
anim
kg
equip
unavail
patient
small
apheresi
may
done
manual
remov
volum
blood
separ
compon
centrifug
return
rest
anim
volum
exchang
standard
protocol
usual
one
plasma
volum
manual
apheresi
requir
remov
approxim
four
sampl
mlkg
exchang
result
progress
decreas
remov
abnorm
substanc
dilut
plasma
replac
fluid
plasmapheresi
shown
definit
valu
treatment
hyperviscos
syndrom
human
canin
patient
nose
et
al
klausner
et
al
paraprotein
confin
primarili
vascular
space
rate
synthesi
slow
remov
everi
week
may
treatment
requir
earli
diseas
certain
immunemedi
diseas
antibodi
product
rapid
remov
result
temporari
improv
rapid
rebound
antibodi
systhesi
requir
followup
immunosuppress
therapi
immunemedi
diseas
like
respond
plasmapheresi
myasthenia
gravi
guillianbarr
syndrom
immunemedi
hemolyt
anemia
thrombocytopenia
plasmapheresi
treatment
choic
thrombot
thrombocytopen
purpura
human
patient
condit
report
anim
therapeut
apheresi
use
clinic
author
other
small
number
dog
matu
et
al
klausner
et
al
amount
specif
patholog
substanc
remov
depend
upon
volum
plasma
exchang
frequenc
procedur
larg
volum
plasma
remov
clot
factor
antithrombin
iii
remov
well
despit
thrombot
hemorrhag
complic
report
mollison
et
al
plasma
level
immunoglobulin
albumin
decreas
result
immunosuppress
decreas
colloid
osmot
pressur
speciesspecif
albumin
avail
anim
replac
fluid
contain
colloid
homolog
plasma
clinic
applic
apheresi
human
anim
continu
expand
diseas
difficult
treat
mean
equip
becom
avail
academ
veterinari
center
procedur
becom
avail
veterinari
patient
well
